Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma.

Mai Ly Thi Nguyen Khac Cuong Bui Tim ScholtaJun XingVikas Bhuria Bence SiposLudwig WilkensNguyen Linh Toan Thirumalaisamy P Velavan Przemyslaw BozkoRuben R Plentz

Published in: Journal of gastroenterology and hepatology (2020)

Interleukin 6 plays an essential role in cholangiocarcinoma carcinogenesis, and siltuximab has the potential to be considered as a new treatment option for cholangiocarcinoma patients.

Keyphrases

monoclonal antibody
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
cancer therapy
risk assessment